

Victor G Vogel, Mhs, Fasco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4907130/publications.pdf>

Version: 2024-02-01

32
papers

9,151
citations

623734

14
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

5112
citing authors

#	ARTICLE	IF	CITATIONS
1	Caregiver-oncologist prognostic concordance, caregiving esteem, and caregiver outcomes. <i>Journal of Geriatric Oncology</i> , 2022, 13, 828-833.	1.0	1
2	Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue. <i>Cancer Prevention Research</i> , 2021, 14, 1-4.	1.5	3
3	Relationships of self-perceived age with geriatric assessment domains in older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1006-1010.	1.0	7
4	Breast cancer risk reduction: Notable achievements and remaining challenges. <i>Breast Journal</i> , 2020, 26, 86-91.	1.0	3
5	The Burdens and Uncertainties of Doing What One Should Do. <i>Cancer Prevention Research</i> , 2017, 10, 431-433.	1.5	2
6	Update on Breast Cancer Risk Reduction Therapy. <i>Current Breast Cancer Reports</i> , 2016, 8, 175-182.	1.0	0
7	Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. <i>BMC Medicine</i> , 2015, 13, 63.	5.5	9
8	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1500-1500.	1.6	5
9	Breast cancer chemoprevention: The saga of underuse continues. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju399-dju399.	6.3	11
10	Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. <i>Lancet, The</i> , 2013, 381, 1827-1834.	13.7	391
11	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2013, 31, 2942-2962.	1.6	279
12	Update on Estrogen Receptorâ€“Positive Breast Cancer Risk Reduction. <i>Current Breast Cancer Reports</i> , 2011, 3, 156-164.	1.0	0
13	Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention. <i>Current Drug Targets</i> , 2011, 12, 1874-1887.	2.1	18
14	Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older. <i>Journal of Clinical Oncology</i> , 2011, 29, 2327-2333.	1.6	177
15	Tipping the Balance for the Primary Prevention of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1683-1685.	6.3	14
16	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 696-706.	1.5	560
17	Carcinoma In Situ Outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. <i>Journal of the National Cancer Institute Monographs</i> , 2010, 2010, 181-186.	2.1	15
18	The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 51-60.	2.4	103

#	ARTICLE	IF	CITATIONS
19	Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer. <i>Menopause</i> , 2008, 15, 782-789.	2.0	49
20	Managing the risk of breast cancer in postmenopausal women. <i>Menopause</i> , 2008, 15, 779-781.	2.0	1
21	Preventing breast cancer in high-risk women, 2008. <i>Oncology</i> , 2008, 22, 666-73; discussion 679, 682, 684.	0.5	3
22	Chemoprevention Strategies 2006. <i>Current Treatment Options in Oncology</i> , 2007, 8, 74-88.	3.0	17
23	Identifying and Screening Patients at Risk of Second Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2027-2032.	2.5	34
24	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2727.	7.4	1,499
25	Atypia in the assessment of breast cancer risk: Implications for management. <i>Diagnostic Cytopathology</i> , 2004, 30, 151-157.	1.0	22
26	Management of the high-risk patient. <i>Surgical Clinics of North America</i> , 2003, 83, 733-751.	1.5	13
27	National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. <i>Clinical Cancer Research</i> , 2003, 9, 495S-501S.	7.0	24
28	Re: Risk/Benefit Assessment of Tamoxifen to Prevent Breast Cancer--Still a Work in Progress?. <i>Journal of the National Cancer Institute</i> , 2000, 92, 574-575.	6.3	4
29	RESPONSE: Re: Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2000, 92, 758-758.	6.3	2
30	Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1829-1846.	6.3	641
31	Assessing risk of breast cancer. <i>Postgraduate Medicine</i> , 1999, 105, 49-58.	2.0	6
32	Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1371-1388.	6.3	5,238